By leveraging a unique genetic feature that separates tumors from normal cells, scientists at A2 Biotherapeutics have designed dual-signal CAR-T cells to address the problem in solid cancers.

AGOURA HILLS, Calif., Dec. 23, 2020 /PRNewswire/ -- A2 Biotherapeutics (www.a2bio.com), a biotechnology company developing innovative cell therapies for cancer patients with solid tumors ...

AGOURA HILLS, Calif.--(BUSINESS WIRE)--A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies to selectively target tumor ...

AGOURA HILLS, Calif.--(BUSINESS WIRE)--A2 Biotherapeutics (www.a2bio.com), a biotechnology company developing innovative cell therapies for cancer patients, today announced its official launch.

Inc. (“A2 Bio”), a biotechnology company focused on the treatment of solid tumors, announced today that key preclinical data related to its proprietary Tmod™ cell therapy platform have been ...

Another cancer-focused startup is joining the fray—A2 Biotherapeutics is launching with $57 million in series A cash to pursue cell therapies for solid tumors, an area in which CAR-T treatments ...

A2-CAR Tregs were generated either by ablating the endogenous T-cell receptor (TCR) constant region alpha (TRAC) locus via CRISPR/Cas9 and then introducing the A2-CAR by lentiviral transduction, or by ...

EBNA Clone 315 displayed exquisite specificity toward its targeted T-cell epitope (TCE) and did not cross-react with the free peptide, HLA-A2 complexes, which carried irrelevant peptides ...